Latest Retinyl palmitate Stories
MIDDLETOWN, Conn., March 19, 2012 /PRNewswire/ -- Hive Health Media has recently published an article that presents several tips for those individuals who are seeking anti-aging solutions. As a cultural movement, as well as a healthcare trend, anti-aging has become a popular activity among many generations. Countless individuals are keen to improve their appearances by restoring their youthful complexions. DermaVeratrol, a skincare product designed to reduce the appearance of fine...
Plus, other options for protecting your skin when the mercury rises YONKERS, N.Y., May 24, 2011 /PRNewswire-USNewswire/ -- In tests of 22 sprays, creams and lotions, Consumer Reports Health identifies nine products that provide excellent protection against the UVB rays that cause sunburn and very good protection against UVA rays, even after immersion in water. Consumer Reports Health identifies three "CR Best Buys:" Up & Up Sport SPF 30 (Target), No-Ad with Aloe and Vitamin E SPF...
Findings refute earlier health warning issued by the Environmental Working Group SCHAUMBURG, Ill., Aug. 10 /PRNewswire-USNewswire/ -- Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology (JAAD) determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans. "Earlier this year,...
A senator asked the U.S. Food and Drug Administration on Sunday to reveal findings on a possible link between a chemical found in most sunscreens and skin cancer. The FDA has been reviewing data from several studies on a potential link between retinal palmitate (RP), a common sunscreen additive, and cases of skin cancer. However, Senator Charles Schumer said no rulings or guidelines have been issued yet. "With the recent reports suggesting a possible link between skin cancer and a...
Results of Two Trials Identify Potential Initiation Dosing Regimen TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study presented today (1). Statistical significance was evidenced at all doses tested (25, 100, and 150 mg equivalent [eq.a]), when given every 4 weeks with a 150 mg eq. initiation dose. A separate...
